Nexalin Technology has secured a US patent for its non-invasive, frequency-based, deep-brain stimulation device aimed at treating Alzheimer’s and dementia.
The US Patent and Trademark Office granted U.S. Patent No 12,011,591, which covers Nexalin’s advanced Gen-2 and Gen-3 medical device.
Related: Elixir Medical wins FDA breakthrough nod for sirolimus-eluting bioadaptor system
This brain stimulation medical device is developed to utilise waveform technology to treat patients in a pain-free and undetectable manner.
The patent is titled ‘Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia’.
Said to be a significant advancement to the predecessor Gen-1 system, the Gen-2 and Gen-3 device employs a new approach to brain stimulation, using strategically placed electrodes on the patient’s head to deliver deep stimulation to brain regions linked with mental health disorders.
According to the company, this technology offers a safe, risk-free and effective treatment option.
The Gen-2 and Gen-3 system is the latest development in Nexalin’s DIFS technology.
Nexalin Technology CEO Mark White said: “The award of this patent marks another major milestone for the company, as we expand our intellectual property to include the treatment of Alzheimer’s and dementia.
“Our growing body of published clinical studies supports the clinical benefits of our device for the treatment of a variety of neurological diseases associated with deep brain structures, ranging from treatment-resistant depression to migraines, anxiety, insomnia, addiction and PTSD.
“Similarly, we believe that our DIFS technology holds the potential to revolutionise the standard of care for additional mental health disorders such as Alzheimer’s and dementia.”
In April 2024, Nexalin secured a US patent related to its non-invasive, frequency-based deep brain stimulation system, Gen-3 HALO Clarity.
